|

QL1706 plus chemotherapy and anlotinib regimen Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University1

Indications

  • Treatment of Recurrent Ovarian Cancer1
  • Cancer1

Other1 trial

QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.